Securities Star data Center News, according to the trading public information released by the Shanghai and Shenzhen Stock Exchange on September 6, 2021, Kellein (002821) was on the list because of securities with a deviation of 7%. This is the first time in the last five trading days that it has been on the list.
By the end of the day, Kellein closed at 357.39 yuan, an increase of 10.0%, with a turnover of 36200 lots.
Judging from the trading data of the day announced by the Dragon and Tiger list, the institutions totaled a net purchase of 126.7539 million yuan. Shenzhen Stock Exchange bought 154.1868 million yuan, sold 95.6269 million yuan, and bought a net 58.5599 million yuan.
The company information of Kelliying (002821) is as follows:
1. One of the leaders in the domestic CMO industry, engaged in customized R & D and customized production of one-stop CDMO services for a number of domestic pharmaceutical companies to provide 1.1 new drug R & D services; representative new drug projects include: treatment of hepatitis C, cardiovascular disease, cystic fibrosis and other projects Signing a strategic cooperation framework agreement with Covance, an American drug research and development company, will provide customers with one-stop service for new drug research and development, and carry out long-term and in-depth cooperation in drug discovery, preclinical trials, clinical trials, drug registration and large-scale production. In May 20, it is proposed to introduce Hillhouse Capital Management Co., Ltd. as a strategic investor and sign a conditional effective strategic cooperation agreement with Hillhouse Capital Management Co., Ltd., to carry out in-depth strategic cooperation in the business areas of small molecules, nucleic acids, biopharmaceutical CDMO and innovative drug clinical research services.
2. The world's leading CDMO solution provider, mainly committed to technological innovation and commercial application of the global pharmaceutical process, providing domestic and foreign large and medium-sized pharmaceutical enterprises and biotechnology enterprises with one-stop CMC services for drug R & D and production. In 19 years, CDMO business revenue was 2.224 billion yuan, accounting for 90.42%.
3. One of the leaders in the domestic CMO industry, engaged in customized R & D and customized production of one-stop CDMO services for a number of domestic pharmaceutical companies to provide 1.1 new drug R & D services; representative new drug projects include the treatment of hepatitis C, cardiovascular disease, cystic fibrosis and other projects
Securities Star valuation Analysis tool shows that Kellein (002821) good company has a rating of 4 stars, a good price rating of 1.5 stars, and a comprehensive valuation rating of 3 stars.
Disclaimer: the relevant content according to the public big data analysis, does not constitute investment advice, the stock market is risky, investment should be cautious.